Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, 'P134 Cell Injection,' which has received Investigational New Drug (IND) ...

Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated in a multi-centre clinical study of ...

The development of the technologies underlying current adenovirus and mRNA vaccines took decades. A key reason why COVID-19 vaccines were developed so quickly was because scientists had already ...

Southern RNA is an Australian CDMO specialising in producing nucleic acid products that support the clinical development of ...

You’ve viewed 1 of 5 articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.

Report Ocean’s latest analysis delves into the “Vietnam Viral Vector and Plasmid DNA Manufacturing Market” Report from 2024 to 2032, covering an array of market facets such as characteristics, size, ...

Complex Pandemic Accord negotiations have been underway since 2021, with 13 formal meetings and numerous informal sessions.